Advik Laboratories Ltd Stock Price Today (NSE: ADVIKLA)
Fundamental Score
Advik Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Advik Laboratories Ltd share price today is ₹2.08, up +0.00% on NSE/BSE as of 17 September 2026. Advik Laboratories Ltd (ADVIKLA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.98 (Cr). The 52-week high for ADVIKLA share price is ₹2.08 and the 52-week low is ₹1.57. The company has a Return on Equity (ROE) of -177.51% and a debt-to-equity ratio of 109.84.
Advik Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Advik Laboratories Ltd share price chart: 4.74% return over the past month. 52-week high ₹2.08, 52-week low ₹1.57.
Advik Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2.08 | ₹2.08 | ₹2.08 | ₹2.08 | 1.45K (Cr) | |
| ₹1.99 | ₹1.99 | ₹1.99 | ₹1.99 | 0.00 (Cr) | |
| ₹1.99 | ₹1.99 | ₹1.99 | ₹1.99 | 0.00 (Cr) | |
| ₹1.99 | ₹1.99 | ₹1.99 | ₹1.99 | 0.00 (Cr) | |
| ₹1.99 | ₹1.99 | ₹1.99 | ₹1.99 | 0.00 (Cr) | |
| ₹1.99 | ₹1.99 | ₹1.99 | ₹1.99 | 0.00 (Cr) | |
| ₹1.99 | ₹1.99 | ₹1.99 | ₹1.99 | 0.00 (Cr) | |
| ₹1.99 | ₹1.99 | ₹1.99 | ₹1.99 | 0.00 (Cr) | |
| ₹1.99 | ₹1.99 | ₹1.99 | ₹1.99 | 0.00 (Cr) | |
| ₹1.99 | ₹1.99 | ₹1.99 | ₹1.99 | 19.19K (Cr) |
Advik Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2.08 | ₹2.08 | ₹2.08 | ₹2.08 | +0.00% | |
| ₹1.90 | ₹1.99 | ₹1.90 | ₹1.99 | +4.74% | |
| ₹1.81 | ₹1.90 | ₹1.81 | ₹1.90 | +4.97% | |
| ₹1.73 | ₹1.81 | ₹1.71 | ₹1.81 | +4.62% | |
| ₹1.73 | ₹1.73 | ₹1.73 | ₹1.73 | +0.00% | |
| ₹1.73 | ₹1.73 | ₹1.73 | ₹1.73 | +0.00% | |
| ₹1.57 | ₹1.73 | ₹1.57 | ₹1.65 | +5.10% | |
| ₹1.76 | ₹1.76 | ₹1.60 | ₹1.65 | -6.25% | |
| ₹1.76 | ₹1.80 | ₹1.68 | ₹1.68 | -4.55% | |
| ₹1.77 | ₹1.85 | ₹1.76 | ₹1.85 | +4.52% | |
| ₹1.90 | ₹1.90 | ₹1.76 | ₹1.76 | -7.37% | |
| ₹2.08 | ₹2.08 | ₹1.99 | ₹1.99 | -4.33% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Advik Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Advik Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ADVIKLA across key market metrics for learning purposes.
Positive Indicators
0 factors identified
No significant strengths identified in current analysis.
Risk Factors
9 factors identified
Below-Average Return on Equity (-177.51%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-135.87%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
High Price-to-Book Ratio (58.03x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Elevated Debt Levels (D/E: 109.84)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-1321.38x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Liquidity Concerns (Current Ratio: 0.23)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Negative Free Cash Flow (₹-5.62 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.58%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Advik Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Advik Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Advik Laboratories LtdAdvik Laborator...Selected✓ ADVIKLA • 531686 | 0/100 | ₹2.08₹2 | ₹3.98₹3.98 | — — | -177.51%Poor -177.51% Poor | -135.87%Poor -135.87% Poor | 109.84Poor 109.8 Poor | 12.20%Good 12.20% Good | — — | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1840.00₹1840 | ₹441471.20₹441471.20 | 36.51Average 36.5 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9322.00₹9322 | ₹247033.00₹247033.00 | 84.58Average 84.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4965.50₹4966 | ₹168062.31₹168062.31 | 79.32Average 79.3 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1119.10₹1119 | ₹111686.18₹111686.18 | 24.94Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1366.00₹1366 | ₹110352.31₹110352.31 | 32.73Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1969.00₹1969 | ₹106375.23₹106375.23 | 97.19Average 97.2 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1165.50₹1166 | ₹97319.25₹97319.25 | 30.12Average 30.1 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1679.80₹1680 | ₹96655.69₹96655.69 | 26.25Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2095.00₹2095 | ₹95793.88₹95793.88 | 17.31Average 17.3 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2280.00₹2280 | ₹94164.00₹94164.00 | 46.07Average 46.1 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price441471.20 Cr
- Divi's Laboratories Limited share price247033.00 Cr
- Torrent Pharmaceuticals Limited share price168062.31 Cr
- Zydus Lifesciences Limited share price111686.18 Cr
- Cipla Limited share price110352.31 Cr
Advik Laboratories Ltd Quarterly Performance
Latest quarterly metrics for ADVIKLA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-9.04%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
12.20%
Compounded annual net profit growth over 5 years
Advik Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ADVIKLA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Advik Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Advik Laboratories Ltd (ADVIKLA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Advik Laboratories Ltd
About ADVIKLA (Advik Laboratories Ltd)
Advik Laboratories Ltd is a research-driven pharmaceutical company dedicated to developing, manufacturing, and marketing innovative and high-quality medicines. Focusing on therapeu...tic areas with unmet medical needs, Advik Laboratories strives to improve patient outcomes and enhance the quality of life for individuals worldwide. The company's state-of-the-art research and development facilities are staffed by a team of experienced scientists and researchers who are committed to discovering and developing novel drug formulations. Advik Laboratories adheres to the highest ethical standards and regulatory requirements, ensuring the safety and efficacy of its products. With a strong emphasis on innovation, quality, and patient-centricity, Advik Laboratories is poised to make a significant impact on the global healthcare landscape. The company's robust product portfolio encompasses a wide range of therapeutic categories, including cardiovascular diseases, diabetes, oncology, and infectious diseases. Advik Laboratories leverages advanced technologies and innovative drug delivery systems to develop differentiated products that address specific patient needs. The company's manufacturing facilities are equipped with advanced technology and adhere to strict quality control measures to ensure that all products meet the highest standards of purity, safety, and efficacy. Advik Laboratories is committed to providing affordable and accessible medicines to patients around the world, partnering with healthcare professionals and organizations to improve access to care and promote better health outcomes. Advik Laboratories has established a strong global presence, with a network of distributors and partners in key markets around the world. The company's commitment to innovation, quality, and patient-centricity has earned it a reputation as a trusted and reliable partner in the pharmaceutical industry. Advik Laboratories is constantly seeking to expand its product portfolio and explore new therapeutic areas to address emerging healthcare needs. The company is dedicated to improving the lives of patients worldwide through the development and delivery of innovative and high-quality medicines. Advik Laboratories is driven by a passion for science, a commitment to innovation, and a desire to make a positive impact on global healthcare.
Company Details
Key Leadership
ADVIKLA Share Price: Frequently Asked Questions
What is the current share price of Advik Laboratories Ltd?
Advik Laboratories Ltd (ADVIKLA) trades at ₹2.08 on NSE and BSE. Market cap ₹3.98 (Cr). Educational data only.
What is the P/E ratio of Advik Laboratories Ltd?
Advik Laboratories Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Advik Laboratories Ltd?
Advik Laboratories Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Advik Laboratories Ltd pay dividends?
Advik Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Advik Laboratories Ltd?
Advik Laboratories Ltd has ROE of -177.51%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Advik Laboratories Ltd?
Advik Laboratories Ltd has debt-to-equity of 109.84.
Is Advik Laboratories Ltd a good investment?
Bull Run gives Advik Laboratories Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.